Originally posted in Cystic Fibrosis News From Medical News Today

Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced positive top line data from its recently concluded Phase 2b study (Once-Daily Respiratory Bronchiectasis Inhalation Treatment – ORBIT-1) with Aradigm’s ciprofloxacin for inhalation (CFI, ARD-3100, LipoquinTM) in patients with non-cystic fibrosis bronchiectasis (BE)…

Originally posted in Cystic Fibrosis News From Medical News Today

Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ciprofloxacin for inhalation for the management of bronchiectasis (BE)…

Originally posted in Cystic Fibrosis News From Medical News Today

Gregory Downey, MD, received the 2010 Recognition Award for Scientific Accomplishments at the American Thoracic Society’s (ATS) International Conference on Monday, May 17. Dr. Downey, Executive Vice President of Academic Affairs and Professor of Medicine, Pediatrics and Immunology at National Jewish Health, has over 190 publications to his credit…

Originally posted in Cystic Fibrosis News From Medical News Today

Bronchiectasis, also known as bronchiectasia, is a lung condition that causes persistent cough and excess phlegm (sputum); it is defined by localized, irreversible dilation (widening) of part of the bronchial tree – the airways widen, become flabby and scarred. Bronchiectasis, along with emphysema, bronchitis and cystic fibrosis is classified as an obstructive lung disease…

Originally posted in Cystic Fibrosis News From Medical News Today

Aradigm Corporation (OTCBB:ARDM) (the “Company”) announced that it dosed the first patient in the U.S…